Biocon Biologics has expanded its partnership with Civica to launch a private-label Insulin Glargine aimed at improving access for the 38.4 million diabetes patients in the U.S. This agreement allows Biocon to manufacture and supply Insulin Glargine to Civica for an exclusive distribution in the U.S.